The global embolization in interventional oncology market is estimated to reach nearly US$ 33.7 Billion in 2021, expanding at a CAGR of 5.4% from 2017 to 2021.
Embolization is a minimally invasive therapy to block a blood vessel. It is commonly used to stop bleeding as well as to stop blood flow to a tumor in order to shrink it or in preparation for removal. Embolization is a procedure that injects substances to try to block or reduce the blood flow to cancer cells. It is an option for some patients with tumors that cannot be removed by surgery, and where tumors are too large to be treated with ablation.
Embolization procedures are used for anti-tumor therapy for tumors in liver (HCC), kidneys (renal carcinoma, lungs or bones), etc. Bland embolisation or Transarterial embolisation (TAE) and transarterial chemoembolization (TACE) have become established treatments for unresectable, intermediate-stage HCC around the world. The rising incidence of HCC in Western countries appears to correlate with the increasing prevalence of hepatitis C virus (HCV).
Bland embolization includes delivery of sub-millimeter microparticles through a catheter inserted in the groin and advanced into the liver under X-ray guidance to get access into the tumor vasculature. Radioembolization technique combines embolization with radiation therapy and is sometimes known as Selective internal radiation therapy (SIRT) or trans-arterial radioembolization. It includes microspheres loaded with a radioactive isotope (Yttrium-90) are injected into the blood vessels feeding a tumor and deliver a lethal dose of radiation into the vessels feeding the tumor thereby causing cell death.
Chemoembolization or trans-arterial chemoembolization (or TACE) combines embolization with chemotherapy. TACE includes delivery of intra-arterial chemotherapy to the liver through a catheter in combination with embolic material to produce ischemia. Drug eluting bead chemoembolization (DEB-TACE) includes delivery of microparticles that are themselves loaded with the chemotherapy agent – doxorubicin – and allow for prolonged elution into the tumor microvessels. In Asia Pacific, TACE with a lipiodol-chemotherapeutic agent suspension and gelatin sponge (GS) particles, are being widely promoted. There is a huge demand in this region for conventional TACE (cTACE). On the other hand, TACE procedures that use drug-eluting beads (a doxorubicinadsorbing type of DEB called DEBDOX, DEB-TACE), are mainly promoted in Europe and the United States.
The global embolization in interventional oncology market report estimates the market size (Revenue US$ million – 2014 to 2021) based on embolization procedure type (bland embolization, radioembolization, transarterial chemoembolization), by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World and forecasts growth trends (CAGR% – 2017 to 2021). The global embolization in interventional oncology market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global embolization in interventional oncology market and profiled in this report include Blockade, Braile Biomedica, BTG International, CeloNova BioSciences, Inc., Cook Medical, Covidien, Depuy Synthes, Merit Medical Systems, Inc., Penumbra, Sequent Medical, Stryker, and Terumo.
1. Procedure Type
1.1. Bland Embolization
1.2. Radioembolization (Selective Internal Radiation Therapy)
1.3. Transarterial chemoembolization
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, South Korea, Rest of APAC)
2.5. Rest of the World
3. Company Profile
3.2. Braile Biomedica
3.3. BTG International
3.4. CeloNova BioSciences, Inc.
3.5. Cook Medical
3.7. Depuy Synthes
3.8. Merit Medical Systems, Inc.
3.10. Sequent Medical
3.12. Terumo Medical Corporation
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/embolization-interventional-oncology-market/